Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Terveystalo, Webcast, Q2'26

By Inderes7/17/2026, 7:30 AM
Terveystalo

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Juuso Pajunen
00:01 - 00:23

Good morning, all. My name is Juuso Pajunen. I will have a dual role today as the host of the Terveystalo Half-Year 2026 Results presentation and as CFO at a later stage. But let's now give the word to Ville Iho, President and CEO of Terveystalo. And let's start the webcast for the half-year results. Ville, please.

Ville Iho
00:24 - 15:56

Thank you and good morning from sunny Helsinki. Let's start by recapping Terveystalo's second quarter. Of course, it was a busy quarter for Terveystalo. We released multiple significant developments, not the least of which were the Silmäasema acquisition, our new financial targets, and our new strategy on the business side. It was still a challenging quarter. The market conditions continued to be abnormally negative. That has been reflected in our revenue line. And that also impacted our profitability and our overall figures. We made adjustments according to the lower volumes. Given the actions we took, we can be pleased with our customer service results. Customer experience numbers are at an all-time high, as well as medical quality. Key indicators are solid, but revenue line obviously negative as well as adjusted EBIT, EPS and also net debt to EBITDA leverage ratio went slightly up. Double-clicking on those negative market drivers. First of all. Public purchases from private healthcare, which are not even seen in this slide, were still almost non-existent. So healthcare counties have insourced quite a bit of their activities, and they are still reorganizing the cooperation models with private healthcare providers. So that was clearly negative. Then from our biggest business, occupational healthcare services, the number of employed persons in Finland, which is the core baseline, was negative. It was still down from the previous Q2. On top of that, the frequency of use was still down and negative. A negative trend is of course negative. That has been reflected in our numbers in occupational healthcare. On the consumer side, it is still negative. The consumer confidence grew. It grew slightly, which is, of course, positive news. All in all, in market volumes we cannot see a positive trend. But in Terveystalo's numbers, actually, the trends are mixed. The consumer-driven services grew during Q2, which is, of course, positive. But given the occupational healthcare headwind, the volumes of Terveystalo were down. Looking at the different segments and business lines, healthcare services are clearly down due to lower volumes and lower revenue, with negative occupational healthcare numbers. A positive fact is that consumer demand grew, especially during the latter part of Q2, and that can be seen as a trend change in that segment, which obviously is positive. Portfolio business is down due to low demand and some structural changes. Obviously, this includes the termination of all outsourcing contracts and the earlier sale of our child welfare business in Sweden. Volumes are still under pressure, but the efficiency development has been really positive. And we can see the trend changing in profitability as well. We cannot yet claim a win in Sweden. But clearly we have been able to turn the trend around and the platform is there. Efficiency is key. Efficiency is evident in those numbers. Of course, the group numbers were negative or the trend was negative. Still double-clicking a little bit on the core classic business within healthcare services, occupational healthcare, our largest segment, is the key to turning around our big machine. We have been conducting a major overhaul in that business line, where commercial operations and digital services have all gone through a significant transformation. We are pleased with the progress of the program. We are focused on our occupational healthcare turnaround. But it is slowly turning a sticky business model where turning around the contracts is gaining momentum. Wins take time. And now, when looking at H2 and future quarters, we do not see a big uptake in the connected employee numbers. It is a rather stagnant view for H2. And bigger gains have been postponed to 2027. We are moving forward. We are making progress. We are renewing our commercial model, our operational model, and introducing world-class digital tools to this business line. But as I said, turning around the bottom line for the business takes time. We are in a very interesting state in our business, where the classic business of course needs full focus in turning around, specifically occupational healthcare. We have a great agenda there, and a great team conducting that part of our agenda. At the same time, we see the whole healthcare services industry is in transformational mode. And for that reason, we have renewed our strategy. We released our strategy earlier and there are a couple of major shifts that we are starting to conduct and new directions toward which we are moving from a value creation point of view. Obviously, there will be significantly more weight on growth rather than protecting profitability. The first example, obviously, is the Silmäasema acquisition. In products and pricing, as megatrends continue to be positive, we of course need to tackle reasons not to buy services from private healthcare providers. And one of them is uncertainty around pricing and packages, and not being adequately transparent towards organizations, corporates, or private consumers. We are moving ahead with more fixed price products, productizing more of our services in retail mode. And with that increase in demand and volumes on the service delivery side, we need to have our eye on value for money. We will continue investing in high-value care chains in brick-and-mortar facilities. So that continues to be a big part of our business going forward. On the other hand, more simplistic services will be steered more aggressively to digital channels. And there we have a great agenda, great tools already in place, and with this combination, value for money for users and payers will be protected and improved going forward, and customer relationships will strengthen with the new expanded, more versatile portfolio. Of course, we need to be able to leverage that customer base that the upcoming Silmäasema acquisition will provide. We are talking about a 2 million customer base only in Finland, and that creates a lot of opportunities for cross-selling and increased, enhanced loyalty. But of course, we need to create an engine for running the loyalty and cross-selling. And that is a focus area for our strategy on top of this. We are making a gradual shift from reactive episodic care chains and complementing them with more continuous care type of models. And that is going to be visible during H2 this year. We are on the move. This is again not a PowerPoint slide. It's a living agenda where we are already moving forward when we are talking about growth. Of course, the biggest and currently most visible components are the Hohde and Silmäasema acquisitions, which will jointly create a 1.55 billion outpatient care masterclass in products and pricing. We started scaling these fixed-price products last year. I will show some deep dives into the impacts of that on service delivery. On top of our earlier world-class digital platform, we have introduced new types of service modalities, specifically an asynchronous service model, which is even more efficient and accessible with a lower price point, but at the same time, still maintains high margins; in terms of customer engagement, as I said, we will start rolling out continuous services during H2. So we are on the move; to double-click on the key points of our already implemented ARC initiatives, obviously the Silmäasema acquisition, as I said, will create a 1.55 billion outpatient care masterclass. Care masterclass jointly with Silmäasema. It is a highly synergistic case with a lot of potential to grow. Grow beyond. Beyond the first phase and in the long term in this market and upcoming markets, it will balance our revenue mix and tilt it more toward the growing private pay domain, which is of course positive for Terveystalo and helps smooth out cycles. As I already mentioned, we are creating a 2 million customer base with respective opportunities for cross-selling and increased loyalty models. This is clearly spot on against our strategic targets and themes. Then, discussing a little bit about this fixed-price model. Some from the audience have asked, why are we moving in this direction? Hasn't it been easy enough to buy services already? But our data shows clearly that the reason not to buy private health care services many times is not the price. As such, it is. It is uncertainty around what you pay for? What do you get? Do you understand what type of package you are getting? And there we need to make a move as an industry. And of course, we need to lead the way. We need to lead the way. We have started scaling fixed-price packages in various services. And we can clearly see a stimulation effect in all of these services that we have launched already. So, tackling those reasons not to buy. Clearly, this will increase volumes and demand, and that is going to be the way forward. Of course, not all of the services can be fixed price because health care is health care. But we can scale this one quite a bit. As I said, we have launched a new asynchronous digital service for use in occupational health care specifically; it is a new modality which is even more efficient than the previous digital chat and video appointment models with a lower price point and a different type of service package. It is fast, it is accessible, and it complements our package and creates new lines for growth in the digital domain. With ARC and our new strategy. Of course, we also released new financial targets. We are still, of course, aiming at an annual adjusted EPS growth of 10%. But we create more headroom for growth with the new leverage ratio and profit distribution targets as stated here. And we are embarking into the ARC growth journey from H2 onwards. And double and triple-clicking on ARC, save the date. Capital Markets Day 2026 will be held on December 1st this year. And there we will share a lot of insights around what has already been done and what's going to happen for Terveystalo in 2027 and onwards. And with that, I will invite you on stage.

Juuso Pajunen
15:58 - 30:52

Good. Thank you, Ville. So let's talk about the financial performance in the first half of the year and especially in the second quarter. First of all, the second quarter was as difficult as expected. We are seeing a decline in revenues, EPS, and EBIT. The market did not materially change. If we look at the conditions during the quarter or when entering the quarter. However, regarding the in-quarter development, it is good to note that especially the consumer market started to pick up and we saw clear stabilization. As for occupational health care. And also in Sweden, we have seen the first glimpses of positive momentum in the market. But despite all of that. Obviously, we are behind as expected for the second quarter with our numbers. On the positive side, our cash flow was solid, especially compared to income statement performance and our NPS, and also the PEI describing the quality of care were at all-time high numbers. But let's then double-click a bit further. So, basically, the weak demand continued in all business areas. If we start from the healthcare services, the occupational health demand remained weak, both from an upper respiratory perspective, and we also had a lower number of connected employees than in the previous year. The consumer out-of-pocket market already showed growth in visits during the quarter, while revenues remained stable. Then if we look at the portfolios, we have the known reduction of outsourcing business, but the public sector remains very sticky. Sweden, as said, is little by little now seeing improvement in our own performance. But also the market is becoming more solid when looking forward. So in healthcare services. If we look at different segments of occupational health, let's look a bit further on the following slide. As you have now become accustomed to regarding the visit growth component, both in occupational and out-of-pocket segments, performance remained steady. The connected employees are now stabilizing. If we compare Q1 to Q2, we are now on a more stable base, but at the same time, it is still below the previous year. And basically, the demand drivers in occupational health remained the same as earlier. At the same time, it is good to note that the visit frequency is stabilizing, and the other KPIs are also becoming more stable as the sales pipeline remained at a good level. But the conversion, as Ville also explained in the new contracts, has been slower than we have expected. Then, if we look at the operational efficiency that continues to be in place, we have taken restructuring measures. We announced statutory negotiations in April that were concluded in May. The outcome of those negotiations will start to support our performance further in the second-half numbers. At the same time, if you look at the decline in revenues and the decline in visits, and then compare the change in our number of employees, for example, you can see that we have taken efficiency measures, and our efficiency remained at a good level. We will obviously continue to address the market conditions going forward. Then looking at the volume development, it continues to be challenging. The underlying factors that contribute to the decline in occupational health visits have not gone anywhere. We did not expect them to go anywhere. Also, when we talk about Q2 numbers. So, basically, due to the general decrease in the employed population, we have employers who are still in cost-cutting mode, and they are addressing the scopes of the contracts. And basically, the number of connected employees in total contributes to the decline in occupational health. But at the same time, as said, the further we have gone during the quarter, we have seen stability and we have seen, for example, the visit frequencies stabilize. And if we are looking at what we have, as we explained, we have a solid sales pipeline. Then on the positive side, when we look at consumers again, the further you look from April to June, we have seen that the consumer market has been picking up and has continued to pick up, and we are now at a visit frequency actually above the second quarter of last year. So all in all, this contributes to a 6.5 percent decline in visits, which is also a better number compared to Q1. But obviously the weight of the upper respiratory disease is smaller in the slower quarter. Looking at the portfolio businesses, our story has continued pretty much as expected, based on the trends from Q1. We have the outsourcing businesses. Those legacy contracts are declining, as we have known and as we have communicated. It is also good to note that these contracts have now become margin-positive, and thus the reduction in revenues is reflected in the reduction of profits. Staffing business and the public sector in total have continued to be in decline, however. However, the rate of decline has continuously stabilized, and the situation has been improving compared to earlier quarters. The public sector in general has been very sticky and remains at a very low level. We have seen some positive glimpses that have not yet materialized, and there are some contract tenders out there in the outsourcing side that will come into play in the latter part of the second half, and also in dental. This is positive. We are gaining market share. We are positive in both revenues and visits, and at the same time, it confirms the trend we see in out-of-pocket customers from a healthcare services perspective. We will get a further boost in our dental business with the acquisition. The approval is pending, and at the moment, we are expecting that we will gain approvals during the third quarter. It would mean that we would be within our own expectations, both from the approval timing perspective and the content perspective when getting to the status that we would get approvals. But obviously it is a process and it is completed when it is completed, but our expectation is after the summer. This will also double our dental business. And it is exactly in line with our strategy. Going into Sweden. I am really happy that now we are, little by little, getting clear improvement. What comes to the EBITDA? EBITDA. In absolute terms and in relative terms, both EBITDA and EBIT are improving against still declining revenues. What we have seen during the quarter and what we have seen during the year is that our efficiency starts to be really strong. And now in the next step, we will have more and more focus on growth, and the operating leverage will support the business. At the same time, the market environment is slightly better than it has been earlier. And going forward, within the quarter, we have seen that, for example, the purchase frequency of our clients has been growing for the first time in a long time, which is a positive signal for the market recovery being in action. Our investments. We have not changed our strategy. We are accelerating our digital efforts. You have seen the M&A, we have announced Silmäasema. We have. We are expecting to close the Hohde deal during Q3. We will continue to invest into future growth. M&A will be selective, will be value-creating, and organic investments. They are focused, especially on digital infrastructure, digitalization, and physical infrastructure, including leasehold improvements and medical equipment. So we have not changed our investment strategy going forward. Looking at the cash flow, Q2 cash flow was actually fairly solid. We are at €175 million in operating cash flow for the last 12 months. And we saw positive development. Positive development, especially in net working capital. The net working capital was supported on the inflow side, with the two last banking days of June being Monday and Tuesday, which is always positive. But all in all, our cash machine continues to work like a Swiss clock. What we deliver on the income statement, we deliver on the balance sheet. Also, our net debt amounted to €560 million, and net debt to adjusted EBITDA was 2.5 and on EBITDA was 2.7. We are within our target range and we have a solid balance sheet. Also when looking forward. At the same time, we all know the announcements on the M&A, and during the quarter, we have renewed our funding structure to fund the ongoing acquisitions and to refinance our old loans. So during the quarter, we have secured €550 million of committed bank financing, both for the Hohde and Silmäasema acquisitions, and we are set to further push the maturities. We have also increased our revolving credit facilities from 80 to 100 million and completed a tap issue under the existing Sustainability-linked bond. With all of that, we are well positioned. The maturity curve is very stable, and it is good to note that the 2027 and 2029 packages also include extension options. So our funding is in a very good place for supporting our strategy. Then, moving on to the market conditions. In the markets, the demand environment is anticipated to improve during the next 12 months and at the end of this year. At the same time, when looking at the trends, they have not materially changed. If we look at the second quarter, the consumer market has been better. In Q1, the trend was downward, although now we see that visits are in growth and revenues are stable. Hence, we are at yellow in the Q2 performance. But at the same time, the next 12 months in all of the market segments remain within the same trends as we have communicated earlier. So the public sector is at a very low level. We see some movement and positive indications that it has bottomed out. It could also be at least stabilizing forward, as consumer pull is good both in out-of-pocket dental and massage services. It is expected to continue on a positive trend. Insurance follows the consumer market fairly well, and occupational health, which has been widely explained during this call, has also been in the red and is expected to stabilize during the year and improve gradually over the next 12 months. And Sweden sees positive indications of market recovery. When looking forward with these topics, let's go to the guidance. You have seen that we updated our guidance two days ago. We expect our full-year adjusted operating profit to be between 120 and €140 million. The previous year's figure was €156 million. Profitability in the first half was clearly below the level of the comparable period in 2025, and that has been impacting the guidance as the environment has been challenging when looking forward. We are expecting the demand environment to gradually improve, and upper respiratory diseases are anticipated to return to long-term averages during the second half of the year. At the same time, we are not expecting material improvement from the connected employees for the second half, and we are expecting the winds to materialize in 2027. No changes for the outsourcing operations in the portfolio businesses, and these do not include material transactions, not Hohde, not Silmäasema. At the same time, it is good to note that if the transaction closes within our expectations, we will be getting a couple of months of performance. So it would not materially change our guidance range at that point in time. With these words, let's invite Ville back and let's start the Q&A. As explained in the beginning, I will act as both CFO and host. Regarding the questions, how should we proceed? We will start with the questions from the conference line. We have nobody sitting in the room. So we start with the questions coming from the webcast listeners, and then we will go. If there are remaining questions posted online, we will address them then.

Operator
30:54 - 31:12

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Sami Sarkamies from Danske Bank Markets. Please go ahead.

Sami Sarkamies
31:14 - 31:31

Hi. I have a couple of questions. We will take these one by one. Firstly, regarding the guidance cut this week, how much of the reduction is driven by Q2 performance and how much is related to the second half outlook.

Ville Iho
31:33 - 32:19

First of all, thanks for the question. It is both. Obviously, we are trailing during Q2 slightly against our targets. So that is one factor. The other factor, as you saw and hopefully was also explained, is the stickiness of the occupational healthcare market. Despite the healthy sales pipeline, we have not been able to materialize a major increase for the connected employee numbers for H2. Rather, the increase is expected to materialize at the year end. So those are the two drivers. Maybe you want to double-click on the ratio between those.

Juuso Pajunen
32:19 - 32:43

Yeah. I would say that, as we said, it is both components and the ratio. This is a bit academic. Maybe we have a bit more emphasis on the occupational health connected employees development compared to the performance in Q2 specifically, which was slightly below our expectations when entering the quarter.

Sami Sarkamies
32:46 - 33:08

Okay. And then continuing on this outlook, if we think about the new midpoint, what needs to happen for you to get there? So what are you assuming regarding second-half developments related to current trading, for example, in Q3, how much improvement is assumed?

Juuso Pajunen
33:08 - 33:46

So basically if we look at the midpoint, it is 130. So the midpoint is 130, which basically means that in the second half, development is broadly in line with the second-half development of the previous year. So what we are expecting there is that the upper respiratory diseases would remain at the long-term average. And we have a slight pickup in the market, let's say, especially on the consumer side, but what we are not expecting is a material increase in the connected employees that would generate revenue during the second half in that guidance.

Sami Sarkamies
33:50 - 34:19

Okay. And then regarding the development in connected employees during the second half, it seems that you are now quite a bit more negative on that. You said that you are expecting the situation to improve at year-end, but not before the year-end. Have you already won those deals? Or do you have visibility on this stronger 2027 performance on this front?

Ville Iho
34:19 - 35:22

Yeah. It is always a mathematical exercise when you are looking at the sales pipeline and a renewal pipeline; as we have discussed earlier, you then estimate the win rate in respective categories. And then you push that forecast forward. There are obviously a couple of wins, one already, which will start next year, January 1st. But really, what we are looking at is a forecast based on our pipelines. And as to being more negative, basically during Q2, the number of connected employees has been stagnant or stable. So there we are, we are not more negative. We are rather slightly more negative on the forecast because we see how the earlier pipeline has turned to actual revenue-generating deals for H2.

Sami Sarkamies
35:25 - 35:37

Okay, so the real change in the second-half outlook within connected employees is that during Q2, your win rates were not as high as expected.

Ville Iho
35:37 - 35:40

You are right regarding new sales. Yes.

Sami Sarkamies
35:44 - 36:06

Uh, okay. And then, you are talking a lot about growth investments, but I am not hearing much regarding cost savings. Your competitors talk more about those. So given the oversupply situation during the past year, can you summarize what cost measures you have taken and what you are still planning to do during the remainder of the year?

Ville Iho
36:07 - 37:24

If I start, then you can follow. We are, of course, when we are talking about frontline services and lower volumes, adjusting, and actually we can be quite pleased with how the operations have been reacting to new situations, where the number of FTEs in our frontline services is lower in ratio than the. Volumes that we have seen. So, we have slightly overreacted in frontline to lower volumes, which is a sign of good ops leadership; where we are not saving, we are not in restructuring mode, and we are not in a saving mode, as we are focused on investments and growth. We have recruited quite a bit of new people to our sales organization, to our digital organization, and to our customer account management organizations. The areas where we see that we need to invest to boost growth. So we are pushing or having our foot on the brake and accelerator at the same time.

Juuso Pajunen
37:25 - 38:04

Yes. And just to complement that, obviously we do not disclose future items in that sense, but if you simply see what we have done, we will continue to react to the market environment. And if you interpret the future, you see that our average numbers were 11% down in Finland for the quarter, and the end of period was actually 13% down. So obviously, as I mentioned during my slides, the restructuring measures taken in the second quarter will support the second-half profitability more than they supported the second-quarter profitability.

Ville Iho
38:04 - 38:33

Yes, maybe one additional element, which we also discussed in our release, is the acceleration of back-office efficiency that we are pursuing. We are now pushing forward with the AI-driven Nova project. It has kicked off and it will yield more efficiency and a lower headcount to respective back office functions.

Sami Sarkamies
38:36 - 39:02

Okay. Then my final question would be on the new commercial offering. Are you planning to introduce more fixed-price contracts? Your competitor has had bad experiences with this. So how do you make sure that, for example, these new pricing models cater for potential cost inflation in the future?

Ville Iho
39:03 - 40:40

First of all, there are two different buckets. You are more alluding to corporate contracts, which are fixed price in our strategy. Of course, that is in play as well, depending on customer needs. We are not big fans of fully fixed-price corporate contracts. The experiences of both clients and suppliers are not great. So there we push more for semi-fixed price contracts where we are jointly setting a target price. And then you have a bonus and malus mechanism around that. And that seems to work well. That is a winning recipe for corporates, not fully fixed price. When we are talking about fixed packages. We are talking about consumer products, be it health check or joint replacement, or that type of clear packages that are clearly priced, easy to buy, and easy to understand regarding what you are getting. As I showed in the presentation, we have data stating clearly that the main reason not to buy from us or from any private player is not the price. As such, it is uncertainty around the price and package. And then when we have applied these fixed models, we can see that it stimulates the market and demand nicely. And that is what we continue scaling.

Sami Sarkamies
40:43 - 40:45

Okay. Thanks. I don't have any further questions.

Operator
40:50 - 40:55

There are no more questions at this time. So I hand the conference back to the speakers.

Juuso Pajunen
40:55 - 41:23

Good. Thank you. Thank you, Sami, for the questions. It is a busy day for analysts. There are a couple of questions coming from online, so I will put them one by one on the table. The first set of questions is related to the pricing that we already touched on in the final remarks. The question from Roni is, has the price competition intensified further during the second quarter, and has it also extended to existing customers rather than only new ones?

Ville Iho
41:23 - 42:54

We discussed the pricing schemes quite a bit earlier. So there is no need to go back there. We also commented on the price competition in our release. So, obviously, we are in an abnormal situation in the healthcare services industry with a really abnormal oversupply situation. That is not going to stay around. That is the first thing to remember. This is from a megatrend point of view. This is a growing business where demand will continue to grow and supply is limited. But in this cycle, we are seeing oversupply. And that, of course, is reflected in higher price pressure. We cannot say that it has intensified. We have seen price pressure in the corporate market since Q4 last year and Q1 this year. It is due to the pressure on corporates and their drive to save costs and oversupply in the market. So, there are no real changes there. We are reacting to the market environment as explained earlier. And as I said, this is not a permanent state of things. This is mostly cyclical. On the other hand, of course, we need to create all the time new pricing schemes, and we need to adjust to customer needs, etc. etc. .

Juuso Pajunen
42:55 - 45:13

Thank you. I believe that covers the question very well. Then there's a second set of questions relating to our guidance and future expectations, specifically regarding how much the flu season drives the guidance range. The second component relates to our statement, especially on Wednesday, that the recovery of net sales and profitability is expected to lag behind the improvement in demand. And there is a question to elaborate on that a bit further. So, how does the work proceed? First of all, let's take the flu season and the totality of the guidance. So as we have stated in our guidance, we expect the flu season to return to long-term averages, which means it will be more intense than it was in the second half of 2025. And obviously, these types of expectations have a range. They are expectations and estimates by nature. That always creates a range. To put that into perspective, you can pick an average price between 100 and 200 euros per episode; however, you need to remember that it is not only a single flu case, but it also depends on the length of the care path and how much it generates in diagnostics. So it is also the type of flu that impacts that as well. And that creates one mix component. Then you need to consider the long-term averages. And what it would mean if it were to remain at the same level, or if it were to return to the long-term averages, and you get a range impact calculated on that part. Then, regarding why we are expecting that the net sales and the profitability will lag behind. This is especially relevant for the connected employees and occupational health. So obviously, when a flu patient comes in for an appointment, that income is recognized immediately. It contributes to our revenue immediately. It contributes to our profit immediately. But when we win an occupational health contract, for example, then obviously only when the covered employees are rolling in, it starts to generate revenue. So that is the reference to the lag.

Ville Iho
45:13 - 45:36

Yeah. As we have always said, especially the occupational health care market is cyclical. We can see the post-cycle effect as a negative phenomenon currently. And when the cycle turns, as it seems to be doing in Finland, there is a lag and delay.

Juuso Pajunen
45:38 - 47:18

Then we have two further questions. Regarding Sweden and our portfolios. Regarding Sweden, let us discuss our performance relative to the market there. And what do we see for the pipeline? It is good to note that in Sweden, since the end of the previous year, we have been net positive in winning. So we have been winning more contracts than we have been losing. And that tendency has continued in 2026. At the same time, it has been countered by the purchase frequency of the clients. And that is why we do not see a revenue increase in the Swedish numbers. But all in all, in the markets, we have been performing fairly well. It is a differently structured and competitive market. But in recent developments, we are net positive. What about wins and portfolios? There is a question regarding profitability. As I explained in my slides, we have been fighting hard to make the legacy contracts at least somewhat profitable. And that is why the decline in those contracts has eaten and will continue to eat into profitability as we move forward in absolute terms. So that one is fair to say, and I think we mentioned it also earlier regarding these. Then we have two questions remaining. The other one relates clearly to Silmäasema and new markets. We think that the Silmäasema platform can be scaled to new markets in the future. Do we see an opportunity to scale up our digital capabilities to new markets as the domestic market is fairly sluggish?

Ville Iho
47:19 - 49:16

Yes. Clearly, starting from Silmäasema, the model they have perfected is unique. It's a winning formula, and there is no reason to believe that it would not be a winning formula in. Other markets with specific fitting characteristics. So, I am optimistic around that one. Silmäasema can scale also outside Finland. And I know that there have been some concrete plans as well. And of course, we will dive deeper into those once the integration starts. Digital platforms. We have now. One concrete example that we are applying with a certain model. So it is a health platform. Our joint venture in occupational health care. We have been busy applying that new world-class digital platform to our corporate clients in Finland. That rollout is progressing well. It is scaling nicely and customer feedback is very positive. Beyond that, we will, of course, focus more on scaling that platform. There are some other assets that we could envision scaling. But mostly, as we have said in our strategy earlier, we want to combine services. We want to be close to the client. Specifically, private paying clients and combining digital assets with services.

Juuso Pajunen
49:17 - 50:03

Thank you. And finally, we have one nitty-gritty point regarding tax consequences. And then we are through. We communicated in Q4 last year that we had a tax audit ongoing. And we had a retrospective component on that, which impacted our Q4 results. The follow-up of that tax audit was concluded in the second quarter of 2026, and there were no material tax consequences for Terveystalo in retrospect for that audit. Thus, we do not have any ongoing tax audits in Terveystalo Group. I thank you all. I wish you a very pleasant summer, and hopefully everybody can get a bit of time off before the summer ends and we are back in business. Thank you all.

Ville Iho
50:03 - 50:04

Thank you. Be safe.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…